Skip to main content

Advertisement

Log in

Effects of Proton Pump Inhibitors on the Small Bowel and Stool Microbiomes

  • Original Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Background

Proton pump inhibitor (PPI) use is extremely common. PPIs have been suggested to affect the gut microbiome, and increase risks of Clostridium difficile infection and small intestinal bacterial overgrowth (SIBO). However, existing data are based on stool analyses and PPIs act on the foregut.

Aims

To compare the duodenal and stool microbiomes in PPI and non-PPI users.

Methods

Consecutive subjects presenting for upper endoscopy without colonoscopy were recruited. Current antibiotic users were excluded. Subjects taking PPI were age- and gender-matched 1:2 to non-PPI controls. Subjects completed medical history questionnaires, and duodenal aspirates were collected using a validated protected catheter. A subset also provided stool samples. Duodenal and stool microbiomes were analyzed by 16S rRNA sequencing.

Results

The duodenal microbiome exhibited no phylum-level differences between PPI (N = 59) and non-PPI subjects (N = 118), but demonstrated significantly higher relative abundances of families Campylobacteraceae (3.13-fold, FDR P value < 0.01) and Bifidobacteriaceae (2.9-fold, FDR P value < 0.01), and lower relative abundance of Clostridiaceae (88.24-fold, FDR P value < 0.0001), in PPI subjects. SIBO rates were not significantly different between groups, whether defined by culture (> 103 CFU/ml) or 16S sequencing, nor between subjects taking different PPIs. The stool microbiome exhibited significantly higher abundance of family Streptococcaceae (2.14-fold, P = 0.003), and lower Clostridiaceae (2.60-fold, FDR P value = 8.61E-13), in PPI (N = 22) versus non-PPI (N = 47) subjects.

Conclusions

These findings suggest that PPI use is not associated with higher rates of SIBO. Relative abundance of Clostridiaceae was reduced in both the duodenal and stool microbiomes, and Streptococcaceae was increased in stool. The clinical implications of these findings are unknown.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Halfdanarson OO, Pottegard A, Bjornsson ES et al. Proton-pump inhibitors among adults: a nationwide drug-utilization study. Ther Adv Gastroenterol. 2018;11:1–11

    Article  Google Scholar 

  2. Jaynes M, Kumar AB. The risks of long-term use of proton pump inhibitors: a critical review. Ther Adv Drug Saf. 2019;10:1–13

    Article  Google Scholar 

  3. Moayyedi P, Eikelboom JW, Bosch J et al. Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin. Gastroenterology. 2019;157:e682

    Article  Google Scholar 

  4. Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol. 2012;107:1001–1010

    Article  CAS  Google Scholar 

  5. Lombardo L, Foti M, Ruggia O, Chiecchio A. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin Gastroenterol Hepatol. 2010;8:504–508

    Article  Google Scholar 

  6. Erdogan A, Rao SS, Gulley D, Jacobs C, Lee YY, Badger C. Small intestinal bacterial overgrowth: duodenal aspiration vs glucose breath test. Neurogastroenterol Motil. 2015;27:481–489

    Article  CAS  Google Scholar 

  7. Pimentel M. The prevalence of small intestinal bacterial overgrowth in irritable bowel syndrome: IBS vs healthy controls (not historical definitions). Gut. 2008;57:1334–1335 (author reply 1335).

    CAS  PubMed  Google Scholar 

  8. Majewski M, McCallum RW. Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: clinical profiles and effects of antibiotic trial. Adv Med Sci. 2007;52:139–142

    CAS  PubMed  Google Scholar 

  9. Fialho A, Fialho A, Thota P, McCullough AJ, Shen B. Small intestinal bacterial overgrowth is associated with non-alcoholic fatty liver disease. J Gastrointest Liver Dis. 2016;25:159–165

    Article  Google Scholar 

  10. Sanchez-Montes C, Ortiz V, Bastida G et al. Small intestinal bacterial overgrowth in inactive Crohn’s disease: influence of thiopurine and biological treatment. World J Gastroenterol. 2014;20:13999–14003

    Article  Google Scholar 

  11. Shah A, Talley NJ, Jones M et al. Small intestinal bacterial overgrowth in irritable bowel syndrome: a systematic review and meta-analysis of case-control studies. Am J Gastroenterol. 2020;115:190–201

    Article  Google Scholar 

  12. Nastaskin I, Mehdikhani E, Conklin J, Park S, Pimentel M. Studying the overlap between IBS and GERD: a systematic review of the literature. Dig Dis Sci. 2006;51:2113–2120. https://doi.org/10.1007/s10620-006-9306-y.

    Article  PubMed  Google Scholar 

  13. Spiegel BM, Chey WD, Chang L. Bacterial overgrowth and irritable bowel syndrome: unifying hypothesis or a spurious consequence of proton pump inhibitors? Am J Gastroenterol. 2008;103:2972–2976

    Article  Google Scholar 

  14. Leite GGS, Morales W, Weitsman S et al. Optimizing microbiome sequencing for small intestinal aspirates: validation of novel techniques through the REIMAGINE study. BMC Microbiol. 2019;19:239

    Article  Google Scholar 

  15. Leite GGS, Weitsman S, Parodi G et al. Mapping the segmental microbiomes in the human small bowel in comparison with stool: a REIMAGINE Study. Dig Dis Sci. 2020. https://doi.org/10.1007/s10620-020-06173-x.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Leite G, Morales W, Weitsman S et al. The duodenal microbiome is altered in small intestinal bacterial overgrowth. PLoS ONE. 2020;15:e0234906

    Article  CAS  Google Scholar 

  17. Klindworth A, Pruesse E, Schweer T et al. Evaluation of general 16S ribosomal RNA gene PCR primers for classical and next-generation sequencing-based diversity studies. Nucleic Acids Res. 2013;41:1

    Article  Google Scholar 

  18. Rezaie A, Buresi M, Lembo A et al. Hydrogen and methane-based breath testing in gastrointestinal disorders: the North American consensus. Am J Gastroenterol. 2017;112:775–784

    Article  CAS  Google Scholar 

  19. Pimentel M, Saad RJ, Long MD, Rao SSC. ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth Am J Gastroenterol. 9000; E-published Ahead of Print.

  20. McMurdie PJ, Holmes S. Waste not, want not: why rarefying microbiome data is inadmissible. PLoS Comput Biol. 2014;10:e1003531

    Article  Google Scholar 

  21. Weiss S, Xu ZZ, Peddada S et al. Normalization and microbial differential abundance strategies depend upon data characteristics. Microbiome. 2017;5:27

    Article  Google Scholar 

  22. Weiss S, Van Treuren W, Lozupone C et al. Correlation detection strategies in microbial data sets vary widely in sensitivity and precision. ISME J. 2016;10:1669–1681

    Article  CAS  Google Scholar 

  23. MacLaren R, Reynolds PM, Allen RR. Histamine-2 receptor antagonists vs proton pump inhibitors on gastrointestinal tract hemorrhage and infectious complications in the intensive care unit. JAMA Intern Med. 2014;174:564–574

    Article  Google Scholar 

  24. Alshamsi F, Belley-Cote E, Cook D et al. Efficacy and safety of proton pump inhibitors for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis of randomized trials. Crit Care. 2016;20:120

    Article  Google Scholar 

  25. Biswal S. Proton pump inhibitors and risk for Clostridium difficile associated diarrhea. Biomed J. 2014;37:178–183

    Article  Google Scholar 

  26. Arriola V, Tischendorf J, Musuuza J, Barker A, Rozelle JW, Safdar N. Assessing the risk of hospital-acquired clostridium difficile infection with proton pump inhibitor use: a meta-analysis. Infect Control Hosp Epidemiol. 2016;37:1408–1417

    Article  Google Scholar 

  27. Choung RS, Locke GR, Schleck CD, Zinsmeister AR, Talley NJ. Associations between medication use and functional gastrointestinal disorders: a population-based study. Neurogastroenterol Motil. 2013;25:e298

    Google Scholar 

  28. Freedberg DE, Toussaint NC, Chen SP et al. Proton pump inhibitors alter specific taxa in the human gastrointestinal microbiome: a crossover trial. Gastroenterology. 2015;149:e889

    Google Scholar 

  29. Hojo M, Asahara T, Nagahara A et al. Gut microbiota composition before and after use of proton pump inhibitors. Dig Dis Sci. 2018;63:2940–2949. https://doi.org/10.1007/s10620-018-5122-4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Vich Vila A, Collij V, Sanna S et al. Impact of commonly used drugs on the composition and metabolic function of the gut microbiota. Nat Commun. 2020;11:362

    Article  CAS  Google Scholar 

  31. Liu S, Chen M, Wang Y et al. Effect of Veillonella parvula on the physiological activity of Streptococcus mutans. Arch Oral Biol. 2020;109:104578

    Article  CAS  Google Scholar 

Download references

Funding

There was no external funding for this study.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Mark Pimentel.

Ethics declarations

Conflict of interest

The authors have no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Weitsman, S., Celly, S., Leite, G. et al. Effects of Proton Pump Inhibitors on the Small Bowel and Stool Microbiomes. Dig Dis Sci 67, 224–232 (2022). https://doi.org/10.1007/s10620-021-06857-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-021-06857-y

Keywords

Navigation